摘要
目的:探讨恶性肿瘤组织DNA倍体异质性与患者临床生物学行为的关系。方法:应用流式细胞仪对163份恶性肿瘤组织DNA倍体异质性进行检测,并分析DNA倍体异质性与患者的临床分期、病理分级及肿瘤转移的关系。结果:各种恶性肿瘤的DNA倍体异质性有明显差异。恶性肿瘤组织DNA倍体异质体检出率随患者临床分期(χ2=119.77,P<0.01)、病理分级(χ2=89.97,P<0.01)的增加而逐渐升高;肿瘤转移者的DNA倍体异质体检出率显著高于未转移者(χ2=113.89,P<0.01)。结论:恶性肿瘤组织DNA倍体异质性是恶性肿瘤的重要生物学特性之一,它和临床生物学行为的关系十分密切,可作为判断肿瘤的恶性程度和预后的重要指标。
Objective：To explore the relationship between DNA ploidy heterogeneity and clinical biological behavior on patients with malignant tumor. Methods ：The DNA ploidy heterogeneity of tumor tissue was measured in 163 patients with malignant tumors by flow cytometry. The relations were analyzed between DNA ploidy heterogeneity and clinical stage, pathological grade, metastasis rate of patients with malignant tumors. Results ：The rates of DNA ploidy heterogeneity were significantly different in different tumors. The rates of heterogeneity raised with increase of clinical stage and pathological grade （P 〈 0.01 ）. The heterogeneity percentage of patients with tumor metastasis was obviously higher than that of patients without non-metastasis （ P 〈 0.01 ）. Conclusion ： As one of the important biological characters of malignant tumors, DNA ploidy heterogeneity is closely related to their clinical biological behaviors and may be regarded as a judgment marker of malignant degree and prognosis of tumors.
出处
《医学研究生学报》
CAS
2007年第3期272-274,共3页
Journal of Medical Postgraduates
基金
江苏省医学重点学科基金资助项目(批准号:苏卫科教[2001]34)
关键词
恶性肿瘤
DNA倍体
异质性
临床分期
病理分级
转移
流式细胞术
Malignant tumor
DNA ploidy
Heterogeneity
Clinical stage
Pathological grade
Metastasis
Flow eytometry
